Exicure, Inc. Receives Positive Listing Determination from Nasdaq
Exicure (Nasdaq: XCUR) has received a positive listing determination from the Nasdaq Hearings Panel. The panel has decided to continue the company's listing on The Nasdaq Capital Market, subject to Exicure demonstrating compliance with all applicable criteria by September 16, 2024. This decision provides Exicure with additional time to meet the necessary requirements for maintaining its Nasdaq listing. The company is actively working to satisfy the terms of the panel's decision and ensure its continued presence on the Nasdaq exchange.
Exicure (Nasdaq: XCUR) ha ricevuto una decisione positiva dal Nasdaq Hearings Panel. Il panel ha deciso di mantenere la quotazione dell'azienda sul Nasdaq Capital Market, a condizione che Exicure dimostri di essere conforme a tutti i criteri applicabili entro il 16 settembre 2024. Questa decisione offre a Exicure ulteriore tempo per soddisfare i requisiti necessari per mantenere la sua quotazione Nasdaq. L'azienda sta lavorando attivamente per soddisfare i termini della decisione del panel e garantire la sua presenza continua sul mercato Nasdaq.
Exicure (Nasdaq: XCUR) ha recibido una determinación positiva de cotización por parte del Nasdaq Hearings Panel. El panel ha decidido continuar con la cotización de la empresa en el Nasdaq Capital Market, siempre que Exicure demuestre el cumplimiento de todos los criterios aplicables antes del 16 de septiembre de 2024. Esta decisión brinda a Exicure tiempo adicional para cumplir con los requisitos necesarios para mantener su cotización en Nasdaq. La empresa está trabajando activamente para satisfacer los términos de la decisión del panel y asegurar su presencia continua en el intercambio Nasdaq.
Exicure (Nasdaq: XCUR)는 Nasdaq Hearings Panel로부터 긍정적인 상장 결정을 받았습니다. 패널은 Exicure가 2024년 9월 16일까지 모든 적용 기준을 준수할 수 있음을 입증하는 조건으로 Nasdaq Capital Market에서의 상장을 계속하기로 결정했습니다. 이 결정은 Exicure에게 Nasdaq 상장을 유지하기 위해 필요한 요건을 충족할 추가 시간을 제공합니다. 이 회사는 패널의 결정의 조건을 충족하고 Nasdaq 거래소에서 지속적으로 존재할 수 있도록 적극적으로 노력하고 있습니다.
Exicure (Nasdaq: XCUR) a reçu une décision positive de cotation du Nasdaq Hearings Panel. Le panel a décidé de maintenir la cotation de l'entreprise sur le Nasdaq Capital Market, à condition qu'Exicure prouve sa conformité à tous les critères applicables d'ici le 16 septembre 2024. Cette décision offre à Exicure un temps supplémentaire pour satisfaire aux exigences nécessaires au maintien de sa cotation sur Nasdaq. L'entreprise travaille activement à satisfaire les conditions de la décision du panel et à garantir sa présence continue sur la bourse Nasdaq.
Exicure (Nasdaq: XCUR) hat eine positive Listungsentscheidung vom Nasdaq Hearings Panel erhalten. Das Panel hat beschlossen, die Listung des Unternehmens am Nasdaq Capital Market fortzusetzen, vorausgesetzt, Exicure kann bis zum 16. September 2024 die Einhaltung aller geltenden Kriterien nachweisen. Diese Entscheidung gibt Exicure zusätzliche Zeit, um die notwendigen Anforderungen für die Aufrechterhaltung seiner Nasdaq-Listung zu erfüllen. Das Unternehmen arbeitet aktiv daran, die Bedingungen der Entscheidung des Panels zu erfüllen und seine fortdauernde Präsenz am Nasdaq-Exchange sicherzustellen.
- Nasdaq Hearings Panel decided to continue Exicure's listing
- Company granted extension until September 16, 2024 to meet compliance criteria
- Exicure still needs to demonstrate compliance with all applicable criteria for continued listing
About Exicure
Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. There can be no assurance regarding our ability to comply with the Panel’s decision and the applicable listing criteria by the deadline or thereafter. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual outcomes to differ materially from the outcomes expressed or implied by this report. Such risks include, among others, the possibility we will not be able to cure existing listing deficiencies, the possibility of additional deficiencies, the risk that the Company may not adequately comply with the terms of the Panel’s decision, and the risk that Nasdaq will ultimately delist the Company's common stock. All such factors are difficult to predict and may be beyond the Company’s control. The Company undertakes no obligation and does not intend to update or revise any forward-looking statements contained herein, except as required by law or regulation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801299565/en/
Josh Miller
847-673-1700
media@exicuretx.com
Source: Exicure, Inc.
FAQ
What decision did Exicure receive from the Nasdaq Hearings Panel on July 31, 2024?
What is the deadline for Exicure (XCUR) to comply with Nasdaq listing requirements?
What actions is Exicure taking in response to the Nasdaq Hearings Panel decision?
